Group 1 - Tevogen Bio Holdings Inc. will have its CEO, Dr. Ryan Saadi, participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] - Dr. Saadi emphasized the importance of addressing market volatility and its impact on patient outcomes, aligning with Tevogen Bio's mission to enhance accessibility to lifesaving treatments [3] Group 2 - The conference will feature a dynamic agenda including 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities designed for growth and collaboration [3] - BioNJ President and CEO Debbie Hart expressed excitement for the panel discussion, highlighting the potential for attendees to gain actionable insights [3]

Core Insights - Tevogen Bio Holdings Inc. will participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] Company Participation - CEO Dr. Ryan Saadi will be featured in a panel discussion titled "Paths to Liquidity: Strategies for Adapting to a Volatile Market" [1] - The panel will include notable industry figures from J.P. Morgan Private Bank, RSM US, and Cantor Fitzgerald, indicating a strong representation of financial expertise [1] Industry Context - The biotechnology industry is currently facing market volatility, which could impact patient outcomes, highlighting the importance of discussions at the conference [3] - The conference will include various activities such as 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities, designed to support growth and collaboration in the industry [3]

Core Insights - Tevogen Bio Holdings Inc. is focused on immunotherapy and artificial intelligence, with recent presentations highlighting their advancements in AI-driven technology for T cell therapies [1][3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified precision T cell therapies aimed at treating infectious diseases and cancers [4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to artificial intelligence [4] Recent Developments - Mittul Mehta, the Chief Information Officer, presented at the AI x Bio Philly event, showcasing Tevogen.AI's technology that accelerates the discovery and development of precision T cell therapies [1][3] - The proprietary technology utilizes computational modeling to predict T cell receptor engagement with immunologically active HLA+ peptide complexes [3] Industry Context - The AI x Bio Philly event gathered innovators, entrepreneurs, and investors to discuss the impact of AI on biotechnology, indicating a growing intersection between these fields [2]

Core Insights - Tevogen Bio Holdings Inc. is focused on immunotherapy and artificial intelligence, with recent presentations highlighting its AI-driven technology for T cell therapies [1][3] - The company aims to develop off-the-shelf, genetically unmodified precision T cell therapies to address significant unmet medical needs in infectious diseases and cancers [4][5] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes for therapeutic development [4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to artificial intelligence [4] Recent Events - Mittul Mehta, the Chief Information Officer, presented at the AI x Bio Philly event, discussing Tevogen.AI's proprietary technology that accelerates the discovery and development of precision T cell therapies [1][3][2] - The event gathered innovators and investors to explore the impact of AI on biotechnology, showcasing the convergence of these fields [2]

Core Insights - Tevogen Bio Holdings Inc. is focused on advancing patient-centric solutions through immunotherapy and artificial intelligence, with a commitment to developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers [1] - The company emphasizes the significant insider ownership, with approximately 74% of outstanding shares held by executive officers and board members, indicating strong confidence in the company's mission and progress [2][3] Company Overview - Tevogen's clinical-stage immunotherapy, Tevogen Bio, aims to create innovative treatments for infectious diseases and cancers [1] - The artificial intelligence initiative, Tevogen.AI, is designed to enhance drug discovery, clinical trial efficiency, and patient access [1] Insider Ownership - Insiders have only sold shares to meet tax obligations related to restricted stock vesting, showcasing their commitment to the company [2] - The high level of insider ownership is noted as a unique advantage compared to other companies in the industry [2] Market Position - The company operates solely in the U.S. and is described as tariff-insensitive, which may provide a buffer against current market volatility [3]

Core Insights - Tevogen Bio Holdings Inc. is focused on advancing patient-centric solutions through immunotherapy and artificial intelligence, with a commitment to developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers [1] - The company emphasizes the significant insider ownership, with approximately 74% of outstanding shares held by executive officers and board members, indicating strong confidence in the company's mission and progress [2][3] Company Overview - Tevogen's clinical-stage immunotherapy, Tevogen Bio, aims to create innovative treatments for infectious diseases and cancers [1] - The artificial intelligence initiative, Tevogen.AI, is designed to enhance drug discovery, clinical trial efficiency, and patient access [1] Insider Ownership - The high level of insider ownership (74%) is noted as a unique advantage compared to other companies in the industry, with insiders primarily selling shares only to meet tax obligations [2] - CEO Dr. Ryan Saadi highlighted the collective confidence of insiders in the company's progress and potential, especially in the context of current market volatility [3] Market Position - Tevogen operates solely in the U.S. and is described as being tariff-insensitive, which may provide a competitive edge in the current economic climate [3]

Core Insights - Tevogen Bio has appointed David E. Banko as Global Head of Government Affairs and Patient Access, bringing over 30 years of experience in market access and health policy [1][2][3] - Mr. Banko will focus on advancing patient access to Tevogen's therapies, engaging with payers, and ensuring Health Technology Assessment readiness, which are critical for the company's commercialization strategies [2][4] - Tevogen Bio is a clinical-stage specialty immunotherapy company developing precision T cell therapies for infectious diseases and cancers, with a strong emphasis on patient accessibility and innovative business models [5][6][7] Company Strategy - The appointment of Mr. Banko is seen as a significant step towards commercialization readiness, emphasizing the need for defined value propositions for various stakeholders in the healthcare ecosystem [4] - Tevogen Bio aims to secure appropriate coding, coverage, and reimbursement for its therapies at launch, which is essential for market access [2][4] - The company has reported positive safety data from its proof-of-concept clinical trials and holds key intellectual property assets, including three granted patents and several pending patents related to artificial intelligence [6] Leadership and Expertise - Mr. Banko's previous roles include positions at Cordis Corp and B. Braun Medical Inc., where he successfully enhanced market access for innovative technologies [3] - Tevogen Bio's leadership team consists of experienced industry leaders and scientists focused on drug development and global product launch [7] - The company believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating disruptive business models to sustain innovation [7]

Core Insights - Tevogen Bio has secured a total of $10 million in non-dilutive grant funding from KRHP LLC, with $2 million already received and an additional $8 million contingent on the Grantor's review of the Company's progress, particularly in its artificial intelligence initiative, Tevogen.AI [1][8] Funding and Financials - The $8 million grant is non-dilutive, meaning it will not affect existing shareholders [1][4] - Tevogen Bio reported operating expenses of $9.7 million for the first three fiscal quarters of 2024, indicating efficient operations [3][8] Technological Advancements - Tevogen.AI has improved the PredicTcell platform by utilizing an expanded dataset of viruses and diseases, supported by wet lab science, to enhance predictive modeling capabilities [2][8] - The Company is expanding its team to further develop predictive models [2] Business Model and Strategy - Tevogen Bio's business model emphasizes long-term success without excessive capital raises or shareholder dilution, aiming for sustainability in the biotech sector [4][5] - The leadership believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating innovative business models to sustain medical innovation [6][5]

As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...